P. Villoslada

Multiscale networks in multiple sclerosis
20247 citationsauthor #37
Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis.
20232 citationsauthor #10
A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple Sclerosis
20235 citationsauthor #1
Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis
202310 citationsauthor #17
Retinal Changes After Acute and Late Optic Neuritis in Aquaporin-4 Antibody Seropositive NMOSD.
20233 citationsauthor #12
Diffusion tensor imaging metrics associated with future disability in multiple sclerosis
202313 citationsauthor #14
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation
20236 citationsauthor #9
Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders
202315 citationsauthor #12
Locus for severity implicates CNS resilience in progression of multiple sclerosis
2023140 citationsauthor #122
Parametric modeling of mechanical effects on circadian oscillators
20232 citationsauthor #5
Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease
20222 citationsauthor #1
Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort.
202215 citationsauthor #23
Brain disconnectome mapping derived from white matter lesions and serum neurofilament light levels in multiple sclerosis: A longitudinal multicenter study
202213 citationsauthor #20
Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis
202226 citationsauthor #21
The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
202220 citationsauthor #23
Longitudinal Retinal Changes in MOGAD
202248 citationsauthor #36
Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
20213 citationsauthor #1
In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis
202112 citationsauthor #16
Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients
202131 citationsauthor #14
APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies
2021181 citationsauthor #48
Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis
20211 citationsauthor #16
Aquaporin-4–neuromyelitis optica spectrum disorder is not a progressive disease
20211 citationsauthor #1
Brain disconnectome mapping and serum neurofilament light levels in multiple sclerosis
20212 citationsauthor #20
Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis
202121 citationsauthor #16
Artificial intelligence extension of the OSCAR‐IB criteria
202138 citationsauthor #15
Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients
202128 citationsauthor #13
Seeing the Finish Line
20211 citationsauthor #1
Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders
202125 citationsauthor #55
Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability
202115 citationsauthor #16
Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis
202011 citationsauthor #1
Reclassifying neurodegenerative diseases
20207 citationsauthor #1
Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years
202027 citationsauthor #17
Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.
202029 citationsauthor #18
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis
202039 citationsauthor #1
The immune signatures of multiple sclerosis: Lessons from twin studies
20204 citationsauthor #1
Author Correction: Reclassifying neurodegenerative diseases
20200 citationsauthor #1
Impact of treatment on cellular immunophenotype in MS
202023 citationsauthor #21
Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis
201914 citationsauthor #16
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
2019146 citationsauthor #25
Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity.
201935 citationsauthor #5
Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study
2019118 citationsauthor #11
Author Correction: Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease
20190 citationsauthor #26
Personalizing medical care for patients with MS
20190 citationsauthor #1
Correction to: Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiation
20190 citationsauthor #10
Harnessing electronic medical records to advance research on multiple sclerosis
201926 citationsauthor #12
MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis
201946 citationsauthor #23
Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study
201975 citationsauthor #21
Remyelination: a good neuroprotective strategy for preventing axonal degeneration?
201910 citationsauthor #1
Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation
201911 citationsauthor #1
Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension (S56.002)
20192 citationsauthor #24
Optimal Inter-Eye Difference Thresholds by OCT in MS: An International Study
201936 citationsauthor #11
Inflammatory activity associated with increased rate of brain and retinal neuro-axonal injury in early MS The aim of this study is to address the effect of local inflammatory activity in brain and retinal neuro-axonal injury along MS course. (P5.2-030)
20190 citationsauthor #18
Predictors of quality of vision impairment in Multiple Sclerosis.
20190 citationsauthor #7
Predictors of vision impairment in Multiple Sclerosis
201826 citationsauthor #16
Anti-Basal Ganglia Antibodies and Streptococcal Infection in ADHD
20185 citationsauthor #4
Author Correction: Subgenual anterior cingulate cortex controls sadness-induced modulations of cognitive and emotional network hubs
20186 citationsauthor #4
Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
20188 citationsauthor #9
Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon.
20187 citationsauthor #10
Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366)
20184 citationsauthor #8
Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis
201838 citationsauthor #13
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial
20186 citationsauthor #8
Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Progressive Disease (P1.420)
201811 citationsauthor #9
Multiple Sclerosis Lesion Segmentation using Improved Convolutional Neural Networks
201814 citationsauthor #4
Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
20185 citationsauthor #9
Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease
201859 citationsauthor #26
Long-term Reduction of Relapse Rate and Confirmed Disability progression after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
20189 citationsauthor #8
Time to Cognitive Worsening in Patients With Relapsing Multiple Sclerosis in Ocrelizumab Phase III Trials (S44.005)
201811 citationsauthor #8
Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis
20184 citationsauthor #2
Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study (P2.160)
20181 citationsauthor #9
Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials
201870 citationsauthor #4
Multicenter reliability of semiautomatic retinal layer segmentation using OCT
201883 citationsauthor #10
Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002)
20183 citationsauthor #8
Burden of neurological diseases in the US revealed by web searches
20175 citationsauthor #3
Correction to: the disruption of mitochondrial axonal transport is an early event in neuroinflammation
20170 citationsauthor #5
Sampling stability and processing parameter-dependent characteristics of the 3D fractal dimension as a marker of structural brain complexity in magnetic resonance images
20170 citationsauthor #6
Revising the Advised Protocol for Optical coherence tomography Study Terminology and Elements (APOSTEL): from recommendations to formal guidelines
20170 citationsauthor #36
Subgenual anterior cingulate cortex controls sadness-induced modulations of cognitive and emotional network hubs
201750 citationsauthor #4
Evaluation of the 3D fractal dimension as a marker of structural brain complexity in multiple-acquisition MRI
201741 citationsauthor #5
Dynamics and heterogeneity of brain damage in multiple sclerosis
201745 citationsauthor #15
Metabolomic signatures associated with disease severity in multiple sclerosis
201792 citationsauthor #1
Systems medicine modeling for multiple sclerosis
20172 citationsauthor #4
OCT as a window to the MS brain
20172 citationsauthor #3
Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making
201711 citationsauthor #4
Retinal inner nuclear layer volume: a potential new outcome measure for optic neuritis treatment trials in MS
20172 citationsauthor #19
Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing
20178 citationsauthor #95
Early retinal atrophy predicts long-term visual impairment after acute optic neuritis
201726 citationsauthor #10
Retinal Nerve Fiber Layer Thickness defines Multiple Sclerosis Patients at Risk of Future Disease Progression (S33.003)
20170 citationsauthor #1
Modeling the Dynamics of the Immune Response
20170 citationsauthor #2
Impairment of decision-making in multiple sclerosis: A neuroeconomic approach
201712 citationsauthor #11
Correction to: the disruption of mitochondrial axonal transport is an early event in neuroinflammation
20170 citationsauthor #5
Methylthioadenosine promotes remyelination by inducing oligodendrocyte differentiation
20173 citationsauthor #10
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.
2017485 citationsauthor #14
Time is vision: The importance of the early discovery and diagnosis of optic neuritis
20174 citationsauthor #1
Epicenters of dynamic connectivity in the adaptation of the ventral visual system
20175 citationsauthor #6
Erratum to: Making sense of big data in health research: towards an EU action plan
20160 citationsauthor #54
Neuroprotective therapies for multiple sclerosis and other demyelinating diseases
201633 citationsauthor #1
Antigen-specific therapy for the treatment of neuromyelitis optica
20160 citationsauthor #2
First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases
201656 citationsauthor #29
A Phase 1b Clinical Trial with Tolerogenic Dendritic Cells for Multiple Sclerosis and Neuromyelitis Óptica (P2.159)
20160 citationsauthor #6
Power estimation for non-standardized multisite studies
201633 citationsauthor #48

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT